Eyenovia, Inc. (EYEN): Price and Financial Metrics

Eyenovia, Inc. (EYEN): $1.82

0.23 (+14.47%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

EYEN Price/Volume Stats

Current price $1.82 52-week high $5.85
Prev. close $1.59 52-week low $1.05
Day low $1.62 Volume 1,016,900
Day high $1.85 Avg. volume 337,737
50-day MA $1.38 Dividend yield N/A
200-day MA $2.47 Market Cap 80.30M

EYEN Stock Price Chart Interactive Chart >


Eyenovia, Inc. (EYEN) Company Bio


Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.


EYEN Latest News Stream


Event/Time News Detail
Loading, please wait...

EYEN Latest Social Stream


Loading social stream, please wait...

View Full EYEN Social Stream

Latest EYEN News From Around the Web

Below are the latest news stories about EYENOVIA INC that investors may wish to consider to help them evaluate EYEN as an investment opportunity.

Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Good day, ladies and gentlemen. And welcome to Eyenovia’s Third Quarter of 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder this conference is being recorded. I will […]

Yahoo | November 14, 2023

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline International as contract manufacturer for Mydcombi cartridge subassemblies and preparations for national launch Company to host conference call and webcast today, November 13th, at 4:30 pm ET NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company

Yahoo | November 13, 2023

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Yahoo | November 9, 2023

Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indicatio

Yahoo | November 6, 2023

Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Anticipates having product available to ship in January 2024NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as

Yahoo | November 2, 2023

Read More 'EYEN' Stories Here

EYEN Price Returns

1-mo 50.41%
3-mo -0.55%
6-mo -36.59%
1-year 8.33%
3-year -57.18%
5-year -51.98%
YTD 11.66%
2022 -59.25%
2021 -33.99%
2020 35.27%
2019 57.19%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!